Who are Trulance's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Elrexfio, Lymphostat B, Prolia, Simponi, Humira, Abrilada.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/plecanatide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Trulance — Competitive Intelligence Brief

Trulance (PLECANATIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Guanylate Cyclase-C Agonist [EPC]. Area: Oncology.

marketed Guanylate Cyclase-C Agonist [EPC] Tumor necrosis factor Oncology Recombinant protein Live · refreshed every 30 min

Target snapshot

Trulance (PLECANATIDE) — Salix. Trulance works by stimulating the guanylate cyclase-C receptor to increase fluid secretion in the intestines.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Trulance TARGET	PLECANATIDE	Salix	marketed	Guanylate Cyclase-C Agonist [EPC]	Tumor necrosis factor	2017-01-01
Elrexfio	elranatamab-bcmm	Pfizer	marketed		Tumor necrosis factor receptor superfamily member 17	2023-01-01
Lymphostat B	BELIMUMAB	Human Genome Sciences Inc.	marketed	B Lymphocyte Stimulator-specific Inhibitor [EPC]	Tumor necrosis factor ligand superfamily member 13B	2011-01-01
Prolia	DENOSUMAB	Amgen	marketed	RANK Ligand Inhibitor [EPC]	Tumor necrosis factor ligand superfamily member 11	2010-01-01
Simponi	GOLIMUMAB	Centocor Ortho Biotech Inc	marketed	Tumor Necrosis Factor Blocker [EPC]	Tumor necrosis factor	2009-01-01
Humira	ADALIMUMAB	AbbVie	marketed	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Abrilada	Adalimumab-Afzb	AbbVie	marketed	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01

Recent regulatory actions (last 90 days)

2026-02-19 — Elrexfio · FDA · approved · US · Pfizer

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Guanylate Cyclase-C Agonist [EPC] class)

AbbVie · 1 drug in this class
Salix · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trulance — Competitive Intelligence Brief. https://druglandscape.com/ci/plecanatide. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab